Core Viewpoint - SenesTech, Inc. has entered into definitive agreements for the immediate exercise of certain outstanding warrants, allowing the purchase of 374,718 shares at a reduced exercise price, aiming to raise capital for working and corporate purposes [1][3]. Group 1: Warrant Exercise and Financial Details - The existing warrants, originally priced at $4.35 per share, will now be exercised at $2.90 per share, generating approximately $1.1 million in gross proceeds before fees [1][3]. - New short-term warrants will be issued, potentially raising an additional $4.3 million if fully exercised [3][5]. - The new short-term warrants will allow the purchase of up to 1,498,872 shares at the same reduced price of $2.90 per share [5]. Group 2: Regulatory and Compliance Information - The resale of shares from the existing warrants has been registered under an effective registration statement [4]. - The new short-term warrants have not been registered under the Securities Act of 1933, meaning they cannot be sold in the U.S. without proper registration or exemption [6]. Group 3: Company Overview - SenesTech focuses on humane pest management solutions, particularly through its Evolve™ rodent birth control product, aiming to create healthier environments and reduce reliance on traditional poisons [8].

Core Viewpoint - SenesTech, Inc. will release its financial results for the fourth quarter and fiscal year 2024 on March 12, 2025, after market close, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - The financial results for the fourth quarter and fiscal year 2024 will be reported after market close on March 12, 2025 [1]. - A conference call is scheduled for the same day at 5:00 pm ET to review the financial results [1]. Group 2: Conference Call Details - Interested parties can join the conference call by dialing (844) 308-3351 or (412) 317-5407 [2]. - A live webcast of the conference call will be available on the Investor Relations section of the company's website [2]. Group 3: Replay Information - A teleconference replay will be available for seven days at (877) 344-7529 or (412) 317-0088, with a replay access code of 7759112 [3]. - A webcast replay will be accessible for 90 days in the Investor Relations section of the company's website [3]. Group 4: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, aiming to create healthier environments [4]. - The company's products, such as Evolve™ rodent birth control, enhance pest management effectiveness while reducing reliance on traditional poisons [4].

Core Insights - SenesTech is expanding its rodent fertility control solutions, Evolve™ Rat and Evolve™ Mouse, into New Zealand and Australia through a partnership with Evicom, targeting the Predator Free 2050 initiative in New Zealand [1][4] - The company anticipates regulatory approval for Evolve in New Zealand by Q3 2025, with shipments expected to start in late Q2 or early Q3 2025 [2] - Evolve offers a sustainable and humane alternative to traditional rodenticides, addressing ecological and economic challenges posed by rodent overpopulation [3][6] Market Opportunities - New Zealand's Predator Free 2050 initiative aims to eradicate invasive predators, with an expected investment of over $4.5 billion, making Evolve a fitting solution for this conservation effort [4] - Australia spends approximately $100 million annually on rodent pest control, with a growth rate exceeding 5% per year, indicating a rising demand for sustainable pest management solutions [5] - SenesTech projects that regional annual demand for Evolve could rapidly reach or exceed $500,000, bolstered by Evicom's partnerships in government and private sectors [6]

PHOENIX, Feb. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech"), a pioneer in humane rodent pest control solutions, is pleased to announce that its Evolve™ Rodent Birth Control product line is now available for purchase on TractorSupply.com. This expansion represents another key milestone in SenesTech's e-commerce growth strategy, bringing its innovative and effective rodent control solution to a broader customer base nationwide.Tractor Supply Company is the largest rural lifestyle retail ...

PHOENIX, Feb. 4, 2025 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), a pioneer in humane pest control solutions, is pleased to announce its plans to enter the Indian rodent pest control market through a partnership with SMark, a well-established distributor based in India. The partnership is cemented by a recently signed letter of intent, underscoring the shared commitment to bringing innovative, non-lethal rodent control solutions to this rapidly growing market.India presents a significant opportunity for ...

Core Insights - SenesTech, Inc. has announced the integration of its rodent birth control product, Evolve™, into Baltimore's rodent management programs, marking a significant step in addressing the city's rodent population issue [1][5] - Evolve™ offers a humane and sustainable solution by targeting rodent reproduction, thereby reducing populations over time without lethal methods [2][4] Company Overview - SenesTech is focused on creating healthier environments through humane pest management solutions, emphasizing fertility control as a means to manage animal pest populations [6] - The company's mission includes enhancing pest management effectiveness while reducing reliance on traditional poisons, aiming for cleaner cities and healthier communities [6] Product Details - Evolve™ is designed to restrict reproduction in both male and female rodents, providing a non-lethal approach to pest control that complements traditional methods [2][4] - The product has received an EPA-designated "minimum risk" classification, ensuring safety for people, pets, wildlife, and the environment [4] Implementation in Baltimore - The City of Baltimore has placed a substantial initial order for Evolve™ and plans to deploy it in high-impact areas as part of its integrated pest management strategy [1][5] - The initiative aims to evaluate the effectiveness of Evolve™ in reducing rodent populations while minimizing environmental and public health risks [5]

Company Overview - SenesTech is a pioneer in humane pest control solutions, specializing in fertility control technologies to manage animal pest populations [8] - The company has developed innovative products like ContraPest®, the only EPA-registered contraceptive for both male and female rats, and Evolve™, an EPA-designated minimum-risk contraceptive soft bait [8] - SenesTech aims to create healthier environments by reducing reliance on traditional poisons and integrating its products seamlessly into pest management programs [8] Product Launch and Distribution - Evolve™ Rodent Birth Control, an innovative rodent control product, will soon be available through Bug Off Pest Control in New York City [1] - Bug Off will market and sell Evolve throughout its network and provide ongoing training to pest management professionals (PMPs) in the Greater New York area [1] - The partnership with Bug Off is expected to accelerate market penetration in New York City, a key and challenging market for rodent control [2][3] Product Features and Effectiveness - Evolve is a soft bait that is highly palatable to rodents, making it easy to deploy in various environments such as barns, garages, homes, gardens, and sheds [4][10] - The product works by reducing rodent fertility, addressing the root cause of overpopulation and providing long-lasting results [10] - Evolve has been tested and proven effective in reducing rodent populations without the use of traditional poisons [4] Market Context - New York City is implementing a rat contraception program, and SenesTech is currently the only manufacturer of products that meet the EPA's requirements for rat contraceptives [7] - The city's program defines "rat contraceptive" as an agent approved by the EPA for reducing reproductive capacity in rats, aligning with SenesTech's product offerings [7] Strategic Partnerships - Bug Off and its President, Andy Linares, are well-respected in the pest management industry, known for their focus on innovation, education, and service [2] - The collaboration with Bug Off is expected to enhance the adoption of Evolve in New York City, leveraging Bug Off's reputation and network [2][3]

Company Announcement - SenesTech, Inc announces Joshua M Moss will join its Board of Directors [1] - Joshua M Moss is co-founder, Managing Director and Portfolio Manager at EAM Global Investors, a boutique investment firm with approximately $3 billion in assets under management [2] - He has over 20 years of experience in institutional investment management, with a proven track record in portfolio management, team leadership and global business development [2] - Previously held senior roles at Allianz Global Investors and began his career at Credit Suisse focusing on investment banking and equity research [3] - Holds an MBA in Finance from UCLA Anderson School of Management and a BA in History from University of California, San Diego [4] Business Outlook - SenesTech and its product Evolve are poised for growth in the coming year and beyond according to Mr Moss [5] - The company has the right team and product to drive this growth [5] Company Overview - SenesTech is committed to creating healthier environments through humane animal pest population management using fertility control [6] - The company is an expert in fertility control technologies and has pioneered products like ContraPest and Evolve [6] - ContraPest is the only EPA-registered contraceptive for both male and female rats [6] - Evolve is an EPA-designated minimum-risk contraceptive soft bait [6] - Both products are designed to integrate seamlessly into pest management programs, enhancing effectiveness while reducing reliance on traditional poisons [6] - The company aims to create cleaner cities, more efficient businesses and happier households with humane, effective and sustainable products [6]

Financial Performance - For the third quarter of 2024, net sales were $482,000, a 34% increase from $360,000 in the same quarter of 2023, driven by the launch of the Evolve product line [83]. - Evolve products accounted for approximately 68%, or $330,000, of revenues in the third quarter of 2024, while ContraPest product revenues declined [83]. - For the nine months ended September 30, 2024, sales reached $1,356,000, a 51% increase from $898,000 in the same period of 2023, with Evolve products representing 63%, or $849,000, of total revenues [84]. - Gross profit for the third quarter of 2024 was $315,000, resulting in a gross profit margin of 65.4%, compared to $176,000 and 48.8% in the third quarter of 2023 [87]. - The company incurred a net loss of $1.5 million for the third quarter of 2024, a 22% decrease from a net loss of $1.9 million in the same quarter of 2023 [83]. Operating Expenses - Total operating expenses for the third quarter of 2024 were $1.86 million, a 12% decrease from $2.13 million in the same quarter of 2023 [83]. - Cost of sales for the third quarter of 2024 was $167,000, or 34.6% of net sales, down from $184,000, or 51.2% of net sales, in the third quarter of 2023 [85]. - Research and development expenses for Q3 2024 were $451,000, an increase of $72,000 from $379,000 in Q3 2023, primarily due to realignment of personnel focus and increased facility costs [90]. - For the nine months ended September 30, 2024, research and development expenses totaled $1,288,000, up $141,000 from $1,147,000 in the same period of 2023 [91]. - Selling, general and administrative expenses for Q3 2024 were $1.4 million, a decrease of $337,000 from $1.7 million in Q3 2023, mainly due to lower personnel-related expenses and professional fees [93]. - For the nine months ended September 30, 2024, selling, general and administrative expenses were $4.4 million, down $856,000 from $5.3 million in the same period of 2023 [94]. Cash and Financing - As of September 30, 2024, the company had an accumulated deficit of $134.8 million and cash and cash equivalents of $2.5 million [77]. - The company expects cash and cash equivalents to be sufficient to fund operations for at least the next four months, contingent on achieving revenue targets [100]. - The company anticipates needing additional financing to achieve future revenue and margin targets [81]. - Cash flows from operating activities used $4.8 million during the nine months ended September 30, 2024, driven by a net loss of $4.9 million [105]. - Net cash provided by financing activities for the nine months ended September 30, 2024, was $2.0 million from warrant exercises and $25,000 from notes payable, offset by $29,000 in repayments [109]. - In comparison, net cash provided by financing activities for the nine months ended September 30, 2023, was $3.0 million from common stock issuance and $44,000 from notes payable, with $11,000 paid for employee withholding taxes [109]. Future Outlook - The company expects to continue incurring significant operating losses for at least the next six months [78]. - The company anticipates ongoing expenses related to marketing and sales of fertility control products, necessitating additional financing [101]. Miscellaneous - Other income for Q3 2024 included $29,000 in miscellaneous income and $11,000 in interest income, compared to $4,000 in interest income in Q3 2023 [95]. - There have been no material changes to critical accounting policies and estimates as disclosed in the Annual Report for the year ended December 31, 2023 [110].

Revenue Growth - Revenues reached $1.4 million in the first nine months of 2024, a 51% increase compared to the same period in 2023[1] - Revenues for the three months ended September 30, 2024, increased to $482,000, up 34% from $360,000 in the same period of 2023[19] - E-commerce sales increased approximately 20% in Q3 2024 compared to Q3 2023, representing about 35% of year-to-date 2024 sales[2] Gross Margin and Profit - Gross margin improved to 65% in Q3 2024 from 49% in Q3 2023, with gross profit dollars increasing by 79%[1] - Gross profit for the nine months ended September 30, 2024, was $699,000, representing a 70% increase compared to $410,000 for the same period in 2023[19] Operating Expenses - Operating expenses decreased by 12% in Q3 2024 compared to Q3 2023, reflecting tight expense control[1] - Selling, general and administrative expenses decreased to $1,411,000 for the three months ended September 30, 2024, down 19% from $1,748,000 in the same period of 2023[19] - Total operating expenses for the nine months ended September 30, 2024, were $5,691,000, down 11% from $6,406,000 in the same period of 2023[19] Product Performance - Evolve Rat product contributed approximately 52% of Q3 2024 revenue, with sales increasing by 11% compared to Q2 2024[2] - Evolve Mouse, launched in May 2024, contributed 17% of Q3 2024 revenue[2] - New product packaging launched for Evolve uses 87% less plastic than traditional pails, enhancing gross margins[3] Financial Loss and Adjusted EBITDA - The net loss for the three months ended September 30, 2024, was $1,513,000, a reduction of 22% compared to a net loss of $1,947,000 in the same period of 2023[19] - Adjusted EBITDA loss for the three months ended September 30, 2024, was $1,418,000, an improvement from a loss of $1,787,000 in the same period of 2023[20] Future Outlook - The Company expects to achieve cash flow breakeven in the near term due to accelerating revenue growth and improved gross margins[4] - The Company is negotiating with New York City for a rat contraception pilot program, responding to city requests[3] Other Financial Metrics - Research and development expenses for the three months ended September 30, 2024, rose to $451,000, a 19% increase from $379,000 in the prior year[19] - Weighted average shares outstanding for the three months ended September 30, 2024, increased significantly to 729,400 from 34,805 in the same period of 2023[19] - Loss per share for the three months ended September 30, 2024, was $(2.07), compared to $(55.93) in the same period of 2023[19] - Other income for the three months ended September 30, 2024, increased to $34,000, compared to $4,000 in the same period of 2023[19]